AN2 Therapeutics (ANTX) vs Compass Therapeutics (CMPX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AN2 Therapeutics (ANTX) has outperformed Compass Therapeutics (CMPX) over the past year, gaining 262.8% versus a loss of 74.8%. Compass Therapeutics is the larger company by market cap ($178.8 million vs $166.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANTX | CMPX |
|---|---|---|
| Share price | $4.40 | $0.993 |
| Market cap | $166.04M | $178.83M |
| 1-day change | -5.98% | +0.98% |
| YTD return | +310.53% | -81.69% |
| 1-year return | +262.79% | -74.78% |
| 5-year return | — | -69.36% |
| EPS (TTM) | $-1.05 | $-0.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.19 | $6.88 |
| 52-week low | $1.00 | $0.829 |
| Distance from 52-week high | -38.80% | -85.57% |
| Analyst consensus | none | buy |
| Avg. price target upside | +104.55% | +448.84% |
| Average volume | 240.21K | 4.14M |
| Shares outstanding | 37.74M | 180.09M |
| Employees | 21 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANTX has outperformed CMPX by 337.6 percentage points over the past year.
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
ANTX vs CMPX FAQ
Which is bigger, AN2 Therapeutics or Compass Therapeutics?
Compass Therapeutics (CMPX) is larger, with a market capitalization of $178.83M compared with $166.04M for AN2 Therapeutics (ANTX).
Which stock has performed better over the past year, ANTX or CMPX?
ANTX returned +262.79% over the past 12 months, compared with -74.78% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are AN2 Therapeutics and Compass Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for AN2 Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Compass Therapeutics.